

# Shuang G Zhao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9603732/publications.pdf>

Version: 2024-02-01

53  
papers

5,824  
citations

156536

32  
h-index

190340

53  
g-index

54  
all docs

54  
docs citations

54  
times ranked

11624  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer. <i>European Urology</i> , 2022, 81, 325-330.                                  | 0.9 | 7         |
| 2  | Reply to M. K. Bos et al. <i>Journal of Clinical Oncology</i> , 2022, 40, 520-522.   | 0.8 | 0         |
| 3  | SEEMLIS: a flexible semi-automated method for enrichment of methylated DNA from low-input samples. <i>Clinical Epigenetics</i> , 2022, 14, 37.   | 1.8 | 3         |
| 4  | Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3633-3641.   | 0.8 | 12        |
| 5  | A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. <i>European Urology</i> , 2021, 79, 374-383.   | 0.9 | 93        |
| 6  | Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 544.  | 3.4 | 82        |
| 7  | Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. <i>European Urology</i> , 2021, 79, 717-721. | 0.9 | 13        |
| 8  | ATR Inhibitor M6620 (VX-970) Enhances the Effect of Radiation in Non-“Small Cell Lung Cancer Brain Metastasis Patient-Derived Xenografts. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2129-2139.                | 1.9 | 21        |
| 9  | Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT Signatures. <i>Npj Genomic Medicine</i> , 2021, 6, 76.   | 1.7 | 10        |
| 10 | Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2926-2937.        | 0.8 | 36        |
| 11 | Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 1644.  | 3.4 | 21        |
| 12 | Prostate cancer research in the 21st century; report from the 2021 Coffey&Holden prostate cancer academy meeting. <i>Prostate</i> , 2021, , .  | 1.2 | 2         |
| 13 | Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate&specific antigen screening in 2012. <i>Cancer</i> , 2020, 126, 717-724.           | 2.0 | 64        |
| 14 | Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 316-323.                      | 2.0 | 6         |
| 15 | SV-HotSpot: detection and visualization of hotspots targeted by structural variants associated with gene expression. <i>Scientific Reports</i> , 2020, 10, 15890.  | 1.6 | 3         |
| 16 | The DNA methylation landscape of advanced prostate cancer. <i>Nature Genetics</i> , 2020, 52, 778-789.   | 9.4 | 198       |
| 17 | Purine metabolism regulates DNA repair and therapy resistance in glioblastoma. <i>Nature Communications</i> , 2020, 11, 3811.  | 5.8 | 103       |
| 18 | Autoantibody Landscape in Patients with Advanced Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6204-6214.   | 3.2 | 10        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | Tumor Immune Microenvironment Clusters in Localized Prostate Adenocarcinoma: Prognostic Impact of Macrophage Enriched/Plasma Cell Non-Enriched Subtypes. <i>Journal of Clinical Medicine</i> , 2020, 9, 1973.   | 1.0  | 10        |
| 20 | Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 646-653.   | 2.0  | 17        |
| 21 | A Signature That May Be Predictive of Early Versus Late Recurrence After Radiation Treatment for Breast Cancer That May Inform the Biology of Early, Aggressive Recurrences. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 686-696. | 0.4  | 11        |
| 22 | Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. <i>Cancer</i> , 2019, 125, 3338-3346.  | 2.0  | 15        |
| 23 | DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway. <i>Clinical Cancer Research</i> , 2019, 25, 5608-5622.   | 3.2  | 17        |
| 24 | Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 1141-1149.   | 0.6  | 17        |
| 25 | Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. <i>Clinical Cancer Research</i> , 2019, 25, 4290-4299.   | 3.2  | 38        |
| 26 | MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 531-538.  | 2.0  | 66        |
| 27 | Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a <i>de novo</i> low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6721-6730.   | 3.2  | 74        |
| 28 | Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications. <i>European Urology Oncology</i> , 2019, 2, 405-412.               | 2.6  | 14        |
| 29 | Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. <i>Clinical Cancer Research</i> , 2019, 25, 2450-2457.   | 3.2  | 52        |
| 30 | The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. <i>Journal of the National Cancer Institute</i> , 2019, 111, 301-310.  | 3.0  | 142       |
| 31 | Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure. <i>European Urology Oncology</i> , 2018, 1, 276-282.  | 2.6  | 6         |
| 32 | PARP1 regulates DNA repair factor availability. <i>EMBO Molecular Medicine</i> , 2018, 10, .  | 3.3  | 52        |
| 33 | Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2018, 24, 3908-3916.  | 3.2  | 24        |
| 34 | The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer. <i>European Urology</i> , 2018, 74, 444-452.  | 0.9  | 55        |
| 35 | Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. <i>Cell</i> , 2018, 174, 758-769.e9.  | 13.5 | 459       |
| 36 | Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study. <i>BJU International</i> , 2017, 120, 351-357.   | 1.3  | 10        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. <i>JAMA Oncology</i> , 2017, 3, 1663.                                     | 3.4 | 219       |
| 38 | MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2. <i>Cancer Research</i> , 2017, 77, 1021-1034.   | 0.4 | 94        |
| 39 | Glioblastoma Therapy Can Be Augmented by Targeting IDH1-Mediated NADPH Biosynthesis. <i>Cancer Research</i> , 2017, 77, 960-970.  | 0.4 | 78        |
| 40 | Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2017, 3, 29.  | 2.3 | 45        |
| 41 | Very Early Salvage Radiotherapy Improves Distant Metastasis-Free Survival. <i>Journal of Urology</i> , 2017, 197, 662-668.  | 0.2 | 76        |
| 42 | Independent surgical validation of the new prostate cancer grade grouping system. <i>BJU International</i> , 2016, 118, 763-769.  | 1.3 | 48        |
| 43 | Maintaining physical activity during head and neck cancer treatment: Results of a pilot controlled trial. <i>Head and Neck</i> , 2016, 38, E1086-96.  | 0.9 | 41        |
| 44 | Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5864-5875.                   | 3.2 | 99        |
| 45 | Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. <i>Lancet Oncology</i> , The, 2016, 17, 1612-1620. | 5.1 | 182       |
| 46 | The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. <i>Nature Communications</i> , 2016, 7, 12791.   | 5.8 | 196       |
| 47 | Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. <i>JAMA Oncology</i> , 2016, 2, 471.  | 3.4 | 46        |
| 48 | The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1777-1786.  | 3.2 | 42        |
| 49 | Development and Validation of a Novel Radiosensitivity Signature in Human Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3667-3677.   | 3.2 | 130       |
| 50 | The landscape of long noncoding RNAs in the human transcriptome. <i>Nature Genetics</i> , 2015, 47, 199-208.  | 9.4 | 2,410     |
| 51 | DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis. <i>Cancer Cell</i> , 2015, 28, 97-113.  | 7.7 | 148       |
| 52 | Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. <i>Radiotherapy and Oncology</i> , 2015, 116, 179-184.      | 0.3 | 61        |
| 53 | A Comprehensive Analysis of CXCL12 Isoforms in Breast Cancer <sup>1,2</sup> . <i>Translational Oncology</i> , 2014, 7, 429-438.   | 1.7 | 33        |